Efficacy and safety of nabufen and sufentanil in the prevention of visceral pain after gynecological laparoscopic surgery:a randomised controlled trial

Abstract

Abstract Background To compare the efficacy and safety of different compatibility schemes in the prevention of visceral pain after gynecological laparoscopic surgery. Methods from April 2019 to April 2020, patients undergoing elective gynecological laparoscopic surgery in our hospital were randomly divided into four groups: group A: sufentanil 3 μ g / kg; group B: low-dose nalbuphine group: 0.1 mg / kg of nabufen + 3 μ g / kg of sufentanil; group C: medium dose of nabufen group: 1 mg / kg of nabufen + 2 μ g / kg of sufentanil; group D: high-dose nabufen 2 There were 30 cases in each group. The degree of pain and the number of adverse reactions at 2, 4, 8, 12, 24 and 48 hours after operation were observed and recorded. The number and dosage of morphine used as a remedial analgesic were recorded. The pain degree was assessed by VAS. The total amount of analgesic pump used, the total number of times of pressing and effective times of pressing were recorded. The adverse reactions also was recorded. Results the analgesic effect of group B was similar to that of group A, while the invalid pressing times, total pressing times and remedial analgesia rate of group C and group D were significantly lower than those of group A ( P < 0.05). There was no significant difference between group C and group D in the number of invalid compressions, the total number of compressions and the rate of remedial analgesia ( P > 0.05), suggesting that increasing the dose of nalbuphine could not significantly increase the analgesic effect. The incidence of postoperative nausea and vomiting, skin pruritus, lethargy and Ramsay Sedation score in group B and group C were significantly lower than those in group A ( P < 0.05). Ramsay Sedation score and incidence of drowsiness were lower than those in group D. Conclusion the combination of 1 mg / kg nabufen and 2 μ g / kg sufentanil is a safe and effective combination scheme for the prevention of visceral pain after gynecological laparoscopic surgery with small adverse reactions. Trial registration: http://www.chictr.org.cn/showproj.aspx?proj=40635 Registration number：ChiCTR1900025076 . Prospectively registered on 10 August 2019.